降糖舒片联合瑞格列奈治疗2型糖尿病的临床研究

目的观察降糖舒片联合瑞格列奈治疗2型糖尿病的临床效果。方法选择2017年2月—2018年8月在宝鸡文理学院医院治疗的2型糖尿病患者165例,随机分为对照组(82例)和治疗组(83例)。对照组患者餐前30min口服瑞格列奈片,初始剂量0.5 mg/次,3次/d,之后根据血糖水平调整用药剂量,最大剂量为4 mg/d。治疗组在对照组基础上口服降糖舒片,5片/次,3次/d。两组患者均连续治疗3个月。观察两组患者临床疗效,同时比较治疗前后两组患者糖化血红蛋白(HbA1c)、餐后2 h血糖(2 h PBG)、空腹血糖(FBG)、胰岛素抵抗指数(HOMA-IR)、胰高血糖素样肽-1(GLP-1)和空腹胰岛素(FINS)水平。结果治疗后,对照组临床有效率为78.05%,显著低于治疗组的93.98%,两组比较差异有统计学意义(P0.05)。治疗后,两组患者HbA1c、2 h PBG和FBG水平均显著下降(P0.05),且治疗组患者HbA1c、2 h PBG和FBG水平明显低于对照组(P0.05)。治疗后,两组患者HOMA-IR显著降低(P0.05),而GLP-1和FINS水平均显著升高(P0.05),且治疗组患者上述胰岛素指标水平明显好于对照组(P0.05)。结论降糖舒片联合瑞格列奈治疗2型糖尿病,可有效改善患者临床症状,降低血糖水平和胰岛素抵抗。

Clinical study on Jiangtangshu Tablets combined with repaglinide in treatment of type 2 diabetes mellitus

Objective To observe the clinical effect of Jiangtangshu Tablets combined with repaglinide in treatment of type 2 diabetes mellitus. Methods Patients (165 cases) with type 2 diabetes mellitus in Hospital of Baoji University of Arts and Sciences from February 2017 to August 2018 were randomly divided into control (82 cases) and treatment (83 cases) groups. Patients in the control group were po administered with Repaglinide Tablets, the initial dose was 0.5 mg/time, three times daily, then adjusted the dose according to the blood glucose level, and the maximum dose was 4 mg/d. Patients in the treatment group were po administered with Jiangtangshu Tablets on the basis of the control group, 5 tablets/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the HbA1c, 2 h PBG FBG, HOMA-IR, GLP-1 and FINS levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 78.05%, which was significantly lower than 93.98% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the HbA1c, 2 h PBG and FBG levels in two groups were significantly decreased (P<0.05), and the blood glucose level in the treatment group was significantly lower than that in the control group (P<0.05). After treatment, the HOMA-IR level in two groups was significantly decreased (P<0.05), but GLP-1 and FINS were significantly increased (P<0.05), and the insulin indexes in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Jiangtangshu Tablets combined with repaglinide in treatment of type 2 diabetes mellitus can improve the clinical symptoms, reduce blood glucose level and insulin resistance.